Novo Nordisk A S annual return on assets (roa)
2020
2021
2022
2023
2024
2025
Novo Nordisk A S Return on Assets (ROA) Growth & History (NVO)
Novo Nordisk A S's return on assets (roa) was 20.31% for fiscal 2025.
View full Novo Nordisk A S company overviewNovo Nordisk A S annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 20.31% | −5.58 pp |
| 2024 | 2024-12-31 | 25.89% | −4.23 pp |
| 2023 | 2023-12-31 | 30.12% | +4.63 pp |
| 2022 | 2022-12-31 | 25.48% | −2.66 pp |
| 2021 | 2021-12-31 | 28.14% | −3.01 pp |
| 2020 | 2020-12-31 | 31.15% | — |
Novo Nordisk A S quarterly return on assets (roa)
Q4.24
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 21.62% | −11.21 pp |
| Q1 2026 | 2026-03-31 | 23.80% | — |
| Q4 2025 | 2025-12-31 | 23.89% | −9.19 pp |
| Q3 2025 | 2025-09-30 | 27.54% | — |
| Q2 2025 | 2025-06-30 | 32.83% | — |
| Q4 2024 | 2024-12-31 | 33.08% | — |
Novo Nordisk A S return on assets (roa) trends
Over the last five fiscal years, Novo Nordisk A S's return on assets (roa) decreased from 31.15% to 20.31%, a change of −10.84 percentage points. The latest reported quarter, Q2 2026, shows 21.62%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Novo Nordisk A S source filings ↗Community posts
Novo Nordisk reports positive STEP Young results in children aged 6 to under 12
Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups receiv ...